The Global Organization for EPA and DHA Omega-3s (GOED) recently published two reports on EPA and DHA omega-3s, the first of which is a biennial report on the finished products market, and the second of which is an analysis of recent clinical studies investigating the relationship between omega-3 and Attention Deficit Hyperactivity Disorder (ADHD).
 
2024 Finished Product Report
 
The 2024 Finished Product Report provides an overview of dietary supplements, pharmaceuticals, foods and beverages, pet nutrition, infant formula, and clinical nutrition/medical foods. Together, these categories reached $52.4 billion in sales in 2023, primarily due to inflation and higher prices.
 
Major takeaways include that the pet nutrition market grew 8.8% in sales to reach $1.5 billion in 2023. The supplement category also grew but primarily due to price hikes associated with the fish oil shortages. The DHA-fortified infant nutrition market is the largest consumer product category, and, despite global birth rates experiencing a decline, the category grew 2.9% in 2023. Sales of all EPA and DHA finished products are poised to increase at an average of 3.3% annually through 2025, GOED projects.
 
ADHD Research
 
The second report, EPA and DHA Supplementation and Attention Deficit Hyperactivity Disorder, explores the latest research on the impact of EPA and DHA omega-3 supplementation on ADHD and associated outcomes. The report was created using GOED’s clinical study database, which catalogs all human clinical studies on EPA and DHA.
 
EPA and DHA have been suggested to play a role in reducing symptoms associated with ADHD, and the report analyzes studies conducted on participants diagnosed with ADHD or assessed using ADHD criteria for symptoms. The report provides key takeaways and suggests next steps for research.
 
The report is available for purchase on GOED’s website for $199, and GOED members have free access to it.